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Summary
This	 is	 a	 joint	 position	 statement	 of	 the	 British	 Society	 of	 Echocardiography,	 the	
British	Heart	Valve	Society	and	the	Society	for	Endocrinology	on	the	role	of	echocar‐
diography	 in	 monitoring	 patients	 receiving	 dopamine	 agonist	 (DA)	 therapy	 for	
hyperprolactinaemia.
1.	Evidence	that	DA	pharmacotherapy	causes	abnormal	valve	morphology	and	dys‐
function	at	doses	used	 in	the	management	of	hyperprolactinaemia	 is	extremely	
limited.	Evidence	of	clinically	significant	valve	pathology	is	absent,	except	for	iso‐
lated	case	reports	around	which	questions	remain.
2.	Attributing	change	in	degree	of	valvar	regurgitation,	especially	in	mild	and	moder‐
ate	tricuspid	regurgitation,	to	adverse	effects	of	DA	in	hyperprolactinaemia	should	
be	avoided	 if	 there	are	no	associated	pathological	 changes	 in	 leaflet	 thickness,	
restriction	 or	 retraction.	 Note	 must	 be	 taken	 that	 even	 where	 morphological	
change	in	leaflet	structure	and	function	may	be	suspected,	grading	is	semi‐quan‐
titative	 on	 echocardiography	 and	may	 vary	 between	 different	machines,	 ultra‐
sound	settings	and	operators.
3.	Decisions	regarding	discontinuation	of	medication	should	only	be	made	after	re‐
view	of	serial	imaging	by	an	echocardiographer	experienced	in	analysing	drug‐in‐
duced	valvulopathy	or	carcinoid	heart	disease.
4.	A	standard	transthoracic	echocardiogram	should	be	performed	before	a	patient	
starts	DA	therapy	for	hyperprolactinaemia.	Repeat	transthoracic	echocardiogra‐
phy	 should	 then	be	performed	at	5	years	 after	 starting	 cabergoline	 in	patients	
taking	a	total	weekly	dose	less	than	or	equal	to	2	mg.	If	there	has	been	no	change	
on	the	5‐year	scan,	repeat	echocardiography	could	continue	at	5‐yearly	intervals.	
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1  | INTRODUC TION
It	is	more	than	10	years	since	the	publication	of	a	large	population‐
based	nested	case‐control	study1	and	an	echocardiographic	preva‐
lence	study2	reporting	an	association	between	the	use	of	pergolide	
and	 cabergoline	 for	 the	 treatment	 of	 symptomatic	 Parkinson's	
disease	(PD)	and	an	increased	risk	of	restrictive	valvular	heart	dis‐
ease.	These	and	other	studies3	led	to	the	voluntary	withdrawal	of	
pergolide	from	the	US	market	 in	2007.	While	pergolide	was	used	
predominantly	 in	 PD,	 cabergoline	 is	 used	more	 commonly	 in	 the	
treatment	 of	 hyperprolactinaemia.	 Dopamine	 agonists	 (DA)	 are	
first‐line	therapy	for	the	treatment	of	hyperprolactinaemia	because	
of	excellent	biochemical	and	tumoral	control	in	the	majority	of	pa‐
tients,	the	alternative	being	surgery	with	or	without	radiotherapy,	
exposing	patients	 to	 the	 risks	of	hypopituitarism.4	Cabergoline	 is	
generally	 the	 agent	 of	 choice	 because	 alternatives,	 such	 as	 bro‐
mocriptine,	require	multiple	daily	doses	and	have	a	less	favourable	
side	effect	profile.	The	use	of	cabergoline	in	PD	and	hyperprolac‐
tinaemia	 differs	 considerably.	Cabergoline	 is	 used	 in	PD	patients	
over	a	shorter	period	(months)	at	much	higher	dose	(typically	3	mg	
a	day)	 compared	 to	 a	much	 longer	period	of	 treatment	 (years)	 at	
lower	doses	(typically	0.5‐1	mg	weekly)	in	hyperprolactinaemic	pa‐
tients.5	Moreover,	while	there	are	a	number	of	effective	alternative	
drugs	in	the	treatment	of	PD,	medical	options	for	the	treatment	of	
hyperprolactinaemia	 are	more	 limited.	 As	 a	 result	 of	 the	 studies	
documenting	an	 increased	 risk	of	valulopathy	 in	PD	patients,	 the	
Medicines	 and	 Healthcare	 products	 Regulatory	 Agency	 (MHRA)	
recommended	 that	 physicians	 in	 the	 United	 Kingdom	 should	 re‐
quest	 baseline	 echocardiography	 to	 exclude	 valvular	 heart	 dis‐
ease	 in	 all	 patients	 before	 starting	 cabergoline	or	 bromocriptine,	
followed	by	a	second	echocardiogram	performed	3‐6	months	after	
commencement	 and	 then	 at	 6‐12‐month	 intervals	while	 continu‐
ing	 on	 the	medication.	 It	 was	 also	 recommended	 that	 treatment	
be	 stopped	 if	 echocardiography	 showed	 worsening	 or	 new	 val‐
vular	 restriction,	 thickening	 or	 regurgitation.	 In	 the	 intervening	
years,	 much	 echocardiographic	 data	 from	 cabergoline‐treated	
hyperprolactinaemic	 patients	 has	 been	 published.	Most	 of	 these	
data	suggest	that	the	risk	of	developing	significant	valvular	heart	
disease	 is	negligible	and	not	a	cause	 for	clinical	concern.	Despite	
this,	constraints	imposed	by	the	working	relationship	between	the	
MHRA	and	the	EMA	dictate	that	the	published	recommendations	
are	unlikely	to	be	revised.	This	Position	Statement,	endorsed	by	the	
British	Society	of	Echocardiography	(BSE),	the	British	Heart	Valve	
Society	 (BHVS)	and	the	Society	 for	Endocrinology	 (SfE)	has	been	
written	to	provide	endocrine	and	cardiac	physicians	with	practical	
guidance	in	this	area	based	on	a	contemporary	review	of	the	avail‐
able literature.
2  | PATHOPHYSIOLOGY
The	possibility	that	cabergoline	might	cause	cardiac	valvulopathy	is	
pharmacologically	 and	mechanistically	 plausible.	 Like	 other	 ergot‐
based	 drugs	 (eg,	 methysergide	 and	 the	 weight	 loss	 drugs	 fenflu‐
ramine	 and	 dexfenfluramine),	 cabergoline	 binds	 to	 the	 serotonin	
receptor	 subtype	 2B	 (5‐HT2B)	 located	 on	 heart	 valves.	 Activation	
of	 these	 receptors	 induces	 valvular	 interstitial	 cell	 mitogenesis	
and	proliferation,	which	 in	 turn	modifies	 the	quantity	 and	quality	
of	 the	 valvular	 extracellular	matrix	 through	 actions	 on	 proteogly‐
cans,	collagen	types	I,	III	and	IV,	and	matrix	metalloproteinases.6	As	
a	result,	valve	leaflets	and	chords	become	thickened,	retracted	and	
If	a	patient	is	taking	more	than	a	total	weekly	dose	of	2	mg,	then	annual	echocar‐
diography	is	recommended.
F I G U R E  1  A,	Tilted	parasternal	long	axis	view	of	the	tricuspid	
valve	demonstrating	thickening,	retraction	and	fixation	of	the	
leaflets.	B,	Colour	flow	Doppler	demonstrating	severe	tricuspid	
regurgitation	(Video	format	can	be	found	in	the	Supporting	
Information)
(A)
(B)
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stiff,	leading	most	commonly	to	valvular	regurgitation	(Figure	1A,B).	
The	 histopathological	 appearance	 of	 valves	 affected	 by	 DA	 ago‐
nists	is	akin	to	that	caused	by	carcinoid	syndrome,	with	deposition	
of	plaque‐like	material	consisting	of	myofibroblasts	within	a	fibro‐
myxoid	stroma.7	An	association	was	found	between	higher	cumula‐
tive	doses	of	pergolide	and	cabergoline	and	the	severity	of	cardiac	
valvular	regurgitation	in	PD	patients	and,	in	particular,	with	the	mi‐
tral	valve	 tenting	area,	a	 subclinical	 index	of	 leaflet	 stiffening	and	
thickening.3	This	quantitative	method	for	measuring	the	impact	of	
DA	on	valve	function	is	important	for	the	interpretation	of	the	pro‐
lactinoma	literature	for	a	number	of	reasons.	Firstly,	without	care‐
ful	blinding,	there	 is	evidence	that	subjective	assessment	tends	to	
result	 in	 over‐estimation	of	 valvulopathy.8	 Secondly,	most	 studies	
report	only	the	degree	of	valve	regurgitation	and	any	assessment	of	
leaflet	thickening	and	retraction	is	subjective.	Thirdly	machine	set‐
tings	are	not	standardized,	particularly	the	use	of	fundamental	 in‐
stead	of	second	harmonic	imaging.	Harmonic	imaging	is	a	technique	
that	employs	the	resonance	characteristics	of	tissue	to	produce	im‐
ages	with	higher	resolution	and	fewer	artefacts	than	conventional	
(fundamental)	imaging.	Harmonic	imaging	is	the	principal	technique	
now	 used	 in	 echocardiography,	 but	 over‐estimates	 leaflet	 thick‐
ness	compared	to	fundamental	imaging.	Finally,	most	studies	within	
the	 prolactinoma	 literature	 only	 reported	 on	 the	 prevalence	 of	
any	 valvular	 lesion	 as	detected	by	echocardiography,	without	dis‐
tinguishing	 cabergoline‐associated	 valvulopathy	 from	 coincidental	
abnormalities	that	may	often	be	found	in	patients	in	the	UK	of	simi‐
lar	age	to	those	studied.9
3  | CURRENT E VIDENCE
Following	publication	of	the	adverse	effects	of	DA	agonists	at	high	
dose	 in	PD,	 several	 groups	published	 single	 institution,	 cross‐sec‐
tional	 case‐control	 studies	 investigating	 the	 link	 between	 chronic	
DA	therapy	at	low	dose	in	hyperprolactinaemia	and	the	presence	of	
valvular	abnormalities	(Table	1).10‐23	These	were	all	limited	by	small	
size.	 Moreover,	 the	 control	 groups	 in	 each	 study	 contained	 only	
healthy	 individuals	 or	 those	 referred	 for	 other	 cardiac	 symptoms,	
eg	 palpitations,	 who	were	 then	 found	 to	 have	 normal	 echocardi‐
ography,	rather	than	untreated	patients	with	hyperprolactinaemia.	
One	 study	 in	 50	 patients	 found	 an	 increase	 in	 the	 prevalence	 of	
moderate	(27/50;	54%)	but	not	of	mild	tricuspid	regurgitation	(TR)	
among	 those	 treated	 with	 cabergoline	 at	 a	 median	 dose	 280	mg	
for	 a	 median	 duration	 of	 72	months	 compared	 to	 controls	 (9/50;	
18%).11	The	distinction	between	mild	and	moderate	TR	was	made	in	
this	paper	by	the	extent	to	which	retrograde	flow	filled	the	atrium,	
which	is	a	method	known	to	be	subject	to	error,	and	technical	and	
haemodynamic	variation.	Furthermore,	the	difference	in	degree	of	
TR	was	found	in	the	absence	of	any	changes	to	the	thickness	or	re‐
striction	of	the	valve	leaflets.	In	another	study	of	78	patients	(mean	
TA B L E  1  Case‐control	studies	and	results
Study (y)
Cases 
(male %)
Controls 
(male %)
Age cases 
±SD
Cumulative dose 
(mg) ± SD
Duration Rx 
(mo) ± SD Summary
Bogazzi	(2008) 100	(21) 100	(16) 41	±	13 279	±	301 67	±	39 No	effect
Boguszewski	(2012) 51	(27) 59	(27) 42.3	±	13.5 239	±	243 38	±	21 ↑	MV	tenting 
↑	Mild	TR	(7.8%	vs	0%)
↑	Mild	PR	(no	statistics	presented)
Colao	(2008) 50	(12) 50	(12) 36.5	±	10.5 414	±	390 81	±	37 ↑	Mod	TR	(54%	vs	18%)
No	other	difference	in	VD
Cordoba	Soriano	(2013) 8	(25) 11	(34) 38.8	±	10.4 158	(median) 46 No	effect
Elenkova	2012 103	(20) 102	(21) 38.6	±	9.93 174	(no	SD) 47	+	286 ↑	Subclinical	fibrosis	(40	vs	23%)
No	other	difference	in	VD
Halperin	(2012) 15	(40) 58	(10) No	data 523	(median) No	data No	effect
Herring	(2009) 50	(60) 50	(60) 51.2	±	15.5 443	±	375 79	±	42 No	effect
Kars	(2008) 47	(28) 78	(26) 46	±	13 363	±	377 62	±	32 ↑	Mild	TR	(41%	vs	26%)
↑	AV	calcification
Lancellotti	(2008) 102	(28) 51	(37) 51	(median) 184	±	105 79	(median) ↑	MV	tenting
No	other	
difference	in	VD
Nacthigall	(2010) 100	(48) 100	(48) 44	±	13 253	±	520 48	±	40 No	effect
Tan	(2010) 72	(26) 72	(28) 36	(median) 126	(median) 53	(median) No	effect
Vallette	(2008) 70	(47) 70	(47) 44	±	13 282	±	271 55	±	22 No	effect
Wakil	(2008) 44	(27) 566	(32) 41.8	±	13.2 279	±	301 44.8 ↑	OR	mild	TR;	mild	PR
No	other	difference	in	VD
Case‐control	studies	in	which	patients	were	being	treated	for	hyperprolactinemia	with	cabergoline	for	a	minimum	of	6	mo,	a	control	group	comparable	
to	cases	without	history	of	DA	therapy	and	had	had	an	echocardiogram	after	≥6	mo	of	cabergoline	treatment.	Values	rounded	to	complete	integer;	
mean	±	SD	unless	stated.
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cumulative	dose	363	mg;	mean	treatment	duration	60	months),	mild	
tricuspid	regurgitation	was	found	more	often	(32/78,	41%)	among	
those	 taking	DA	 agonists	 than	 in	 controls	 (20/78,	 26%),	 although	
there	was	 no	 graded	 association	with	 cumulative	 dose	 and	 there	
was	no	difference	in	‘clinically	significant’	valve	disease.12	Again,	the	
difference	in	degree	of	TR	was	found	in	the	absence	of	any	changes	
to	the	thickness	or	restriction	of	the	valve	leaflets.	The	same	study	
also	suggested	an	increase	in	aortic	calcification,	which	is	difficult	to	
understand	from	a	pathophysiological	perspective	and	has	not	been	
replicated	elsewhere.	Thereafter,	two	more	similar‐sized	case‐con‐
trolled	studies	suggested	other	morphological	changes.13,17	In	102	
patients	 (mean	 cumulative	 cabergoline	 dose	 204	mg;	mean	 treat‐
ment	duration	79	months),13	 there	was	an	 increase	 in	mitral	valve	
tenting	 area	 but	 no	 difference	 in	 leaflet	 thickness	 and	 no	 change	
in	any	other	valves.	 In	103	patients	 (mean	cumulative	cabergoline	
dose	174	mg;	mean	 treatment	duration	46	months),17	 there	was	a	
new	category	of	 ‘sub‐clinical	 fibrosis’,	defined	by	 increased	 leaflet	
echogenicity	and/or	increased	cusp	thickness	(>3	mm	mitral;	>2	mm	
other	valves)	but	with	no	difference	in	the	degree	of	regurgitation.	
These	data	also	contrast	with	the	results	of	10	similar	sized,	single	
institution	case‐control	studies	that	found	no	link	between	DA	use	
and	significant	restrictive	valve	defects	or	regurgitation.10,14‐16,18‐23 
Finally,	 a	 large	 multi‐centre	 cross‐sectional	 study	 based	 in	 the	
United	Kingdom	of	747	patients	taking	DA	agonists	(median	caber‐
goline	 dose	 152	mg)	 showed	 no	 association	 between	 cumulative	
doses	of	cabergoline	or	bromocriptine	and	the	age‐corrected	preva‐
lence	of	valvular	abnormalities.24	In	summary,	case‐control	studies	
investigating	DA‐agonist	valvulopathy	in	hyperprolactinaemia	have	
provided	poor	quality	data,	using	different	diagnostic	criteria,	mul‐
tiple	 testing	 in	 small	 groups	 and	 lack	 of	 standardised	 assessment	
of	valve	morphology.	There	are	isolated	case	reports	of	restrictive	
valve	disease	after	cabergoline	but	these	have	either	been	in	cases	
treated	with	high	dose8,25	or	in	patients	with	co‐morbidity,26 and in 
one	case	developing	bowel	obstruction	after	diagnosis	of	dopamine	
agonist	 valvulopathy	without	 exclusion	of	 co‐existing	neuroendo‐
crine tumour.27
In	 addition	 to	 the	 cross‐sectional,	 case‐control	 studies,	 there	
have	 been	 three	 studies	with	 serial	 follow‐up	 (Table	 2).	 The	 first,	
small,	 single‐centre	 study	 examined	 45	 patients	 receiving	 cab‐
ergoline	 for	 prolactinoma	 (mean	 cabergoline	 dose	 401	mg)	 with	
baseline	 and	 then	 repeat	 echocardiography	 at	 2	years,	 and	 found	
neither	valve	stenosis	nor	development	of	valvular	regurgitation.28 
In	a	follow‐up	of	192/747	patients	from	the	original	cross‐sectional	
study	by	Drake	et	al,	with	median	duration	of	cabergoline	therapy	
34	 (24‐42)	months,	no	association	was	 found	between	cumulative	
doses	of	cabergoline	and	clinically	significant	valvular	abnormality.5 
The	 third	 study	 followed	 100	 subjects	 for	 a	median	 interval	 62.5	
(34.8‐77)	 months	 between	 echocardiography	 following	 a	 median	
total	duration	of	cabergoline	therapy	for	124.5	months	(median	dose	
277.8	mg)	and	found	no	significant	alterations	in	valve	structure	or	
function.29	One	of	these	studies	had	a	median	follow‐up	of	10	years,	
although	the	potential	expected	duration	of	treatment	with	caber‐
goline	can	sometimes	be	longer.T
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Meta‐analyses	have	been	performed	however,	 that	suggest	a	
small	effect	may	be	present,	although	again	there	are	 limitations	
to	these	statistical	studies.30,31	Firstly,	the	meta‐analyses	have	all	
been	influenced	by	data	from	one	early	single	centre	case‐control	
study,	in	which	27/50	(54%)	patients	compared	to	9/50	(18%)	con‐
trols	were	reported	as	having	moderate‐severe	TR11	Interestingly,	
the	same	group	subsequently	reported	a	follow‐up	study	in	which	
there	were	no	reported	differences	in	the	risk	of	TR	between	con‐
trols	 and	 cabergoline‐treated	 patients.	 Secondly,	 although	 these	
meta‐analyses	 indicated	a	possible	 increased	risk	of	mild‐moder‐
ate	tricuspid	regurgitation,	they	were	not	associated	with	the	typ‐
ical	 features	of	valve	thickening	and	restriction,	and	no	clinically	
significant	valve	lesions	were	identified.	If,	as	is	widely	accepted,	
it	is	the	interaction	of	cabergoline	with	5HT2B	receptors	that	me‐
diates	the	abnormal	valvular	function	then,	by	analogy	with	carci‐
noid	heart	disease,	 this	should	be	accompanied	by	characteristic	
changes	in	valve	morphology	(leaflet	thickening,	restricted	move‐
ment	and	calcification).	A	major	barrier	to	progress	in	the	field	is	
the	 fact	 that	 long‐term,	detailed	 studies	of	 the	 size	 sufficient	 to	
exclude	an	effect	would	be	costly	to	perform	and	require	consid‐
erable	 expertise	 to	 ensure	 consistent,	 reliable	 and	 quantitative	
echocardiographic	 assessment.	 It	 is	 important	 to	note	 that	 in	 all	
studies	 performed,	 bromocriptine	 has	 not	 been	 implicated	 with	
any	valvular	abnormalities.
Alternative	imaging	modalities,	for	example	cardiovascular	mag‐
netic	 resonance	 imaging,	do	not	provide	adequate	 spatial	 or	 tem‐
poral	 resolution	 to	 compete	 with	 echocardiography	 for	 detailed	
assessment	of	valve	structure	and	function.	Moreover,	a	prospec‐
tive,	placebo‐controlled	design	amongst	young	women	with	hyper‐
prolactinaemia	and	oligo‐amenorrhea	would	be	unethical;	and	any	
effects	of	cabergoline	would	be	impossible	to	separate	from	those	
caused	 by/associated	 with	 restoration	 of	 physiological	 oestrogen	
secretion.	The	expectation	that	existing	clinical	networks	could	pro‐
duce	accurate,	large	volume	data	by	applying	current	MHRA	guide‐
lines	 on	 surveillance	 by	 echocardiography	 also	 appears	 unlikely,	
since	adherence	 to	current	 recommendations	 is	poor.	 In	a	 service	
evaluation	performed	by	NHS	Highland	(North),	only	2/45	patients	
started	 on	 a	 DA	 agonist	 had	 echocardiography	 prior	 to	 starting	
therapy.33
4  | RECOMMENDATIONS ON 
SURVEILL ANCE
Echocardiography	is	accepted	as	the	gold	standard	technique	for	as‐
sessment	of	native	valve	structure	and	function.34	The	detection	of	
changes	in	structure	and	function	in	native	valves	may	be	subtle	and	
echocardiography	should	be	performed	by	properly‐trained,	accred‐
ited	 professionals.35	 In	 each	 case,	 a	 standard	 transthoracic	 study	
should	be	performed	following	minimum	standards.36	In	addition	to	
this,	 however,	 careful	 attention	 should	be	 taken	 to	perform	 semi‐
quantitative	 assessment	of	 valve	 structure	 and	 function	 to	detect	
the	 changes	 typical	 of	DA	agonist	 therapy.	Although	 there	 are	no	
methods	validated	for	assessment	in	DA	agonist	therapy	per	se,	the	
changes	to	be	detected	are	the	same	as	those	in	patients	with	car‐
cinoid	heart	disease,	for	which	there	are	validated	scoring	systems	
with	high	feasibility	and	discriminatory	value.37	Of	these,	the	most	
sensitive	 and	 specific	 is	 an	echocardiographic	 scoring	 system	 that	
assesses	leaflet	thickening,	mobility	and	morphology,	severity	of	val‐
vular	regurgitation	and	stenosis,	and	the	haemodynamic	effects	on	
(right)	ventricular	size	and	function	with	good	inter‐observer	agree‐
ment.38	Moreover,	 this	 incorporates	assessment	of	all	 four	cardiac	
valves,	 although	 focusses	 on	 haemodynamically‐significant	 right‐
sided	valvular	lesions	through	secondary	effects	on	right	ventricular	
size	and	function,	which	have	been	most	frequently	identified	in	the	
literature	in	DA	agonist	therapy	(Table	3).	Although	tenting	area	has	
been	used	to	quantify	stiffening,	this	has	not	been	validated	in	large	
studies	and	repeatability	and	reproducibility	are	not	known,	so	that	
this	is	not	a	recommended	feature	for	screening	and	follow‐up.
Given	 that	 one	 of	 the	 major	 difficulties	 with	 the	 existing	 lit‐
erature	 is	 the	 separation	of	 valve	disease	due	 to	DA	agonist	 ther‐
apy	from	pre‐existing	changes	 in	valve	structure	and	function,	 it	 is	
recommended	 that	all	patients	 starting	DA	agonist	 therapy	should	
undergo	a	transthoracic	echocardiogram	before	drug	therapy	is	com‐
menced	(Table	4).	An	increase	in	valve	score	may	then	be	interpreted	
in	 the	 clinical	 context,	 considering	 the	 age	 and	 sex	of	 the	patient,	
the	impact	of	other	factors	on	valve	leaflet	thickening,	mobility	and	
morphology	(eg,	ageing,	chronic	kidney	disease),	and	likely	impact	of	
DA	agonist	(total	dosage	and	exposure).	The	main	problem	in	clinical	
practice	will	be	the	use	of	such	a	score	 in	patients	who	have	been	
 Normal = 0 Mild = 1 Moderate = 2 Severe = 3
Leaflet	thickening 0 + ++ +++
Leaflet	mobility 0 ↓ ↓↓ ↓↓↓
Leaflet	morphology Normal Stiff	and	
straight
Mild retraction Moderate‐se‐
vere 
retraction
Stenosis 0 Mild Moderate Severe
Regurgitation 0 Mild Moderate Severe
RV	dimension 0 >42	mm RV	=	LV RV	forming	the	
LV	apex
RV	function 0 ↓ ↓↓ ↓↓↓
Adapted	from	Bhattacharya	et	al.33
TA B L E  3  Scoring	system	for	patients	
receiving	dopamine	agonist	therapy
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on	a	DA	agonist	for	some	time	and	in	whom	there	may	be	changes	
identified	on	echocardiography.	There	have	been	no	prospective	val‐
idation	studies	of	a	scoring	system	and	therefore,	it	is	not	possible	to	
give	a	value	or	‘score’	above	which	a	patient	should	be	categorized	as	
affected	by	DA‐valvopathy.	The	sensitivity	of	the	scoring	system	for	
identifying	changes	in	patients	with	carcinoid	increases	with	increas‐
ing	score,	with	a	median	score	in	those	affected	12	(range	8‐21)	and	
in	those	not	affected	2	(IQR	1‐3).37	It	could	be	argued	that	routinely	
performing	a	 transthoracic	echocardiogram	before	drug	 therapy	 is	
commenced	may	be	unnecessary	and	that	doing	an	echocardiogram	
if	 the	dose	 is	 increased	above	2	mg/wk	may	be	sufficient.	The	ap‐
proach	in	this	guideline	is	conservative,	since	the	existing	case‐con‐
trol	and	longitudinal	follow‐up	studies	cannot	definitively	exclude	a	
small	effect	in	the	longer	term.	Moreover,	given	the	semi‐quantita‐
tive	nature	of	echocardiographic	evaluation	of	the	changes	described	
in	DA	valvulopathy	and	the	fact	that	some	of	these	changes	can	be	
seen	in	other	conditions,	assessment	before	initiation	of	drug	ther‐
apy	is	considered	a	pragmatic	solution	pending	further	data.
Given	 the	worst‐case	 scenario	 for	 potential	 progression	 based	
on	the	largest	cohort	with	serial	follow‐up,5	it	is	recommended	that	
repeat	 transthoracic	 echocardiography	 should	 be	 performed	 at	
5	years	after	starting	cabergoline	 in	patients	 taking	a	 total	weekly	
dose	≤2	mg.	If	there	has	been	no	change	on	the	5‐year	scan,	repeat	
echocardiography	could	continue	at	5‐yearly	 intervals.	Within	 this	
time	 interval,	 there	has	been	no	evidence	of	major	clinical	change	
affecting	patient	outcome.	There	is	an	option	for	annual	surveillance	
with	auscultation,	although	there	are	no	data	regarding	accuracy	of	
this	approach	relative	to	the	use	of	echocardiography.39	If	a	patient	
is	taking	a	total	weekly	dose	of	more	than	2	mg,	then	annual	echo‐
cardiography	 is	 recommended,	 although	 the	 number	 of	 these	 pa‐
tients	is	small	(see	Table	4).	Once	cabergoline	has	been	stopped,	no	
further	echocardiography	is	warranted	assuming	that	no	moderate	
or	severe	valve	abnormality	has	been	identified.
Given	 that	 grading	 is	 semi‐quantitative,	 with	 subjective	 as‐
sessment	of	leaflet	thickening,	mobility	and	morphology,	it	is	vital	
that	 follow‐up	 studies	are	cross‐checked	by	a	different	observer	
blinded	to	the	initial	echocardiographic	score.	Specifically,	where	
there	 is	 a	 discrepancy	 >2	 points	 in	 score,	 an	 echocardiographer	
with	experience	of	patient	monitoring	for	DA	valvulopathy	or	with	
experience	in	patients	who	have	carcinoid	heart	disease	should	an‐
alyze	the	serial	studies	available	in	the	patient	before	any	decision	
is	made	regarding	discontinuation	of	medication.	It	is	critical	to	un‐
derstand	that	changes	in	degree	of	regurgitation	alone,	for	exam‐
ple	from	mild	to	moderate	tricuspid	regurgitation,	should	not	on	its	
own	be	sufficient	to	alter	clinical	management,	especially	without	
morphological	change	in	leaflet	motion,	thickness	or	retraction.
5  | CONCLUSIONS
Evidence	that	dopamine	agonists	cause	valvulopathy	akin	to	carcinoid	
heart	disease	in	patients	with	hyperprolactinaemia	is	limited	to	a	very	
small	number	of	 isolated	case	reports	 in	which	the	cumulative	doses	
used	were	very	high	and	not	dissimilar	to	those	reported	in	the	original	
studies	of	PD	patients.	The	 finding	of	valvular	 regurgitation	 in	a	pa‐
tient	taking	cabergoline	for	hyperprolactinaemia	does	not,	 in	the	ab‐
sence	of	typical	valvular	structural	changes,	mandate	discontinuation	
of	the	drug.	Any	decision	about	discontinuation	of	the	drug	should	be	a	
multi‐disciplinary	one,	in	discussion	with	the	patient,	and	consideration	
should	be	given	 to	 replacement	with	bromocriptine.	Ongoing	collec‐
tion	of	high‐quality	data,	via	collaborative	audit	and	study	 initiatives,	
together	with	post‐marketing	reporting	(eg,	“yellow	card”	reports	in	the	
UK)	of	independently	confirmed	cases,	is	strongly	encouraged.
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Recommendations  
1. All	patients	should	undergo	echocardiography	before	commencing	DA	
therapy
2. Patients	taking	a	dose	of	cabergoline	of	≤	2mg/weekly	should	undergo	
surveillance	echocardiography	at	5	y
3. Patients	taking	a	dose	of	cabergoline	of	>2	mg/wk	should	undergo	
annual	echocardiography
4. Patients	taking	a	dose	of	≤2	mg/wk	who	develop	a	change	in	valve	
function	should	undergo	annual	echocardiography	if	treatment	is	to	
continue
5. Decisions	regarding	discontinuation	of	medication	should	only	be	made	
after	review	of	serial	imaging	by	an	echocardiographer	experienced	in	
analysing	drug	induced	valvulopathy	or	carcinoid	heart	disease
TA B L E  4  Summary	of	
recommendations	for	patients	receiving	
dopamine	agonist	therapy	in	
hyperprolactinaemia
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